Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet

Journal of Endocrinology

Volumn 194, Issue 3, 2007, Pages 539-550

  Barbuio, Raquel ^a   Milanski, Marciane ^a   Bertolo, Manoel B ^a   Saad, Mário J ^a   Velloso, Lício A ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; INSULIN; INSULIN RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE 2; PROTEIN KINASE B; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR FKHR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; LIPID DIET; LIPID STORAGE; LIVER FIBROSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CYTOKINES; DIETARY FATS; FATTY LIVER; FIBROSIS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MODELS, ANIMAL; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34748903504     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/JOE-07-0234     Document Type: Article

References (51)

1. Angulo P 2002 Nonalcoholic fatty liver disease. New England Journal of Medicine 346 1221-1231.
2. Anty R, Bekri S, Luciani N, Saint-Paul MC, Dahman M, Ianneli A, Amor IB, Staccini-Myx A, Huet PM, Gugenheim J et al. 2006 The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. American Journal of Gastroenterology 101 1824-1833.
3. Araujo EF, De Souza CT, Gasparetti AL, Ueno M, Boschero AC, Saad MJ & Velloso LA 2005 Short-term in vivo inhibition of insulin receptor substrate-1 expression leads to insulin resistance, hyperinsulinemia, and increased adiposity. Endocrinology 146 1428-1437.
4. Araujo de Vizcarrondo C, Carrillo de Padilla F & Martin E 1998 Fatty acid composition of beef, pork, and poultry fresh cuts, and some of their processed products. Archivos Latinoamericanos de Nutricion 48 354-358.
5. Arend WP 2002 The mode of action of cytokine inhibitors. Journal of Pheumatology 65 16-21.
6. Baig NA, Herrine SK & Rubin R 2001 Liver disease and diabetes mellitus. Clinics in Laboratory Medicine 21 193-207.
7. Balasubramanyam M, Sampathkumar R & Mohan V 2005 Is insulin signaling molecules misguided in diabetes for ubiquitin-proteasome mediated degradation. Molecular and Cellular Biochemistry 275 117-125.
8. den Boer MA, Voshol PJ, Schroder-van der Elst JP, Korsheninnikova E, Ouwens DM, Kuipers F, Havekes LM & Romijn JA 2006 Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. Endocrinology 147 4553-4558.
9. Browning JD & Horton JD 2004 Molecular mediators of hepatic steatosis and liver injury. Journal of Clinical Investigation 114 147-152.
10. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM & Hobbs HH 2004 Prevalence of hepatic stearosis in an urban population in the United States: impact of ethnicity. Hepatology 40 1387-1395.
11. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J & Shoelson SE 2005 Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nature Medicine 11 183-190.
12. Calegari VC, Alves M, Picardi PK, Inoue RY, Franchini KG, Saad MJ & Velloso LA 2005 Suppressor of cytokine signaling-3 Provides a novel interface in the cross-talk between angiotensin II and insulin signaling systems. Endocrinology 146 579-588.
13. Carvalheira JB, Ribeiro EB, Folli F, Velloso LA & Saad MJ 2003 Interaction between leptin and insulin signaling pathways differentially affects JAK-STAT and PI 3-kinase-mediated signaling in rat liver. Biological Chemistry 384 151-159.
14. Chang JT & Lichtenstein GR 2006 Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. Nature Clinical Practice. Gastroenterology and Hepatology 3 220-228.
15. Day CP &James OF 1998 Steatohepatitis: a tale of two 'hits'? Gastroenterology 114 842-845.
16. Diehl AM, Li ZP, Lin HZ & Yang SQ 2005 Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 54 303-306.
17. Elinav E, Pappo O, Sklair-Levy M, Margalit M, Shibolet O, Gomori M, Alper R, Thalenfeld B, Engelhardt D, Rabbani E et al. 2006 Amelioration of non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels. Journal of Pathology 208 74-81.
18. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M & Hotamisligil GS 2002 A central role for JNK in obesity and insulin resistance. Nature 420 333-336.
19. Hotamisligil GS 2006 Inflammation and metabolic disorders. Nature 444 860-867.
20. Iimuro Y, Gallucci RM, Luster MI, Kono H & Thurman RG 1997 Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 26 1530-1537.
21. Kubo M, Hanada T & Yoshimura A 2003 Suppressors of cytokine signaling and immunity. Nature Immunology 4 1169-1176.
22. Latter CZ & Farrell GC 2006 Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? Journal of Hepatology 44 253-261.
23. Lee Y, Wang MY, Kakuma T, Wang ZW, Babcock E, McCorkle K, Higa M, Zhou YT & Unger RH 2001 Unger RH, Liporegularion in diet-induced obesity. The antisteatotic role of hyperleptinemia. Journal of Biological Chemistry 276 5629-5635.
24. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A & DeCarli LM 2004 Model of nonalcoholic steatohepatitis. American Journal of Clinical Nutrition 79 502-509.
25. Lin XZ, Horng MH, Sun YN, Shiesh SC, Chow NH & Guo XZ 1998 Computer morphometry for quantitative measurement of liver fibrosis: comparison with Knodell's score, colorimetry and conventional description reports. Journal of Gastroenterology and Hepatology 13 75-80.
26. Mackenzie CG, Mackenzie JB, Reiss OK & Wisneski JA 1970 Identification of albumin-bound fatty acids as the major factor in serum-induced lipid accumulation by cultured cells. Journal of Lipid Research 11 571-582.
27. Medina J, Fernandez-Salazar LI, Gircia-Buey L & Moreno-Otero R 2004 Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 27 2057-2066.
28. Paz K, Hemi R, LeRofth D, Karasik A, Elhanany E, Kanery H & Zick Y 1997 A molecular basis for insulin resistance, Elevated serine/threoriine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. Journal of Biological Chemistry 272 29911-29918.
29. Pimenta WP, Saad MJ, Paccola GM, Piccinato CE & Foss MC 1989 Effect of oral glucose on peripheral muscle fuel metabolism in fasted men. Brazilian Journal of Medical and Biological Research 22 465-476.
30. Pitombco C, Araujo EP, De Souza CT, Pareja JC, Geloneze B & Velloso LA 2006 Amelioration of diet-induced diabetes mellitus by removal of visceral fat. Journal of Endocrinology 191 699-706.
31. Poniachik J, Csendes A, Diaz JC, Rojas J, Burdiles P, Maluenda F, Smok G, Rodrigo R & Videla LA 2006 Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine 33 252-257.
32. Saad MJ, Carvalho CR, Thirone AC & Velloso LA 1996 Insulin induces tyrosine phosphorylation of JAK2 in insulin-sensitive tissues of the intact rat. Journal of Biological Chemistry 271 22100-22104.
33. Saltiel AR & Kahn CR 2001 Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 799-806.
34. Scott DL & Kingsley GH 2006 Tumor necrosis factor inhibitors for rheumatoid arthritis. New England Journal of Medicine 355 704-712.
35. Scott AM, Atwater I & Rojas E 1981 A method for the simultaneous measurement of insulin release and B cell membrane potential in single mouse islets of Langerhans. Diabetologia 21 470-475.
36. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, Kollias G, Ghrayeb J, Vilcek J & Daddona PE 1995 The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7 15-25.
37. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT & Caro JF 1990 Liver pathology in morbidly obese patients with and without diabetes. American Journal of Gastroenterology 85 1349-1355.
38. De Souza CT, Araujo EP, Bordin S, Ashimine R, Zollner RL, Boschero AC, Saad MJ & Velloso LA 2005a Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology 146 4192-4199.
39. De Souza CT, Araujo EP, Prada PO, Saad MJ, Boschero AC & Velloso LA 2005b Short-term inhibition of peroxisome proliferator-acrivated receptor-gamma coactivator-1 alpha expression reverses diet-induced diabetes mellitus and hepatic stearosis in mice. Diabetologia 48 1860-1871.
40. Spahr L, Rubbia-Brandt L, Frossard JL, Giostra E, Rougemont AL, Pugin J, Fischer M, Egger H & Hadengue A 2002 Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology 37 448-455.
41. Thirone AC, Scarlett JA, Gasparetti AL, Araujo EP, Lima MH, Carvalho CR, Velloso LA & Saad MJ 2002 Modulation of growth hormone signal transduction in kidneys of streptozotocin-induced diabetic animals: effect of a growth hormone receptor antagonist. Diabetes 51 2270-2281,
42. Tilg H & Diehl AM 2000 Cytokines in alcoholic and nonalcoholic steatohepatitis. New England Journal of Medicine 343 1467-1476.
43. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N, Toda K, Kaneko T, Horie Y et al. 2006 Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcohohc steatohepatitis in mice. Gut 55 415-424.
44. Trinder P 1969 Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. Journal of Clinical Pathology 22 158-161.
45. Ueki K, Kondo T, Tseng YH & Kahn CR 2004 Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. PNAS 101 10422-10427.
46. Velloso LA, Kampe O, Hallberg A, Christmanson L, Betsholtz C & Karlsson FA 1993 Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. Journal of Clinical Investigation 91 2084-2090.
47. Velloso LA, Folli F, Perego L & Saad MJ 2006 The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes/Metabolism Research and Reviews 22 98-107.
48. Williams R 2006 Global challenges in liver disease. Hepatology 44 521-526.
49. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP & Taylor SM 2003 A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. Journal of Immunology 171 5514-5520.
50. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI & Thurman RG 1999 Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 117 942-952.
51. Zou Y, Li J, Lu C, Wang J, Ge J, Huang Y, Zhang L & Wang Y 2006 High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Science 79 1100-1107.